BIOVIT Stock Overview
Bio Vitos Pharma AB (publ) operates as a medical technology company in Sweden and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Bio Vitos Pharma AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.23 |
| 52 Week High | kr0.59 |
| 52 Week Low | kr0.085 |
| Beta | 1.55 |
| 1 Month Change | 24.25% |
| 3 Month Change | 34.12% |
| 1 Year Change | -49.45% |
| 3 Year Change | -93.45% |
| 5 Year Change | -96.96% |
| Change since IPO | -96.23% |
Recent News & Updates
Shareholder Returns
| BIOVIT | SE Medical Equipment | SE Market | |
|---|---|---|---|
| 7D | -8.4% | -0.7% | -1.7% |
| 1Y | -49.4% | -8.8% | 8.1% |
Return vs Industry: BIOVIT underperformed the Swedish Medical Equipment industry which returned -7.8% over the past year.
Return vs Market: BIOVIT underperformed the Swedish Market which returned 8.8% over the past year.
Price Volatility
| BIOVIT volatility | |
|---|---|
| BIOVIT Average Weekly Movement | 13.0% |
| Medical Equipment Industry Average Movement | 7.1% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in SE Market | 13.0% |
| 10% least volatile stocks in SE Market | 3.4% |
Stable Share Price: BIOVIT's share price has been volatile over the past 3 months.
Volatility Over Time: BIOVIT's weekly volatility has decreased from 26% to 13% over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 1 | Jesper Birgemo | biovitospharma.com |
Bio Vitos Pharma AB (publ) operates as a medical technology company in Sweden and internationally. The company develops and commercializes Helge, which detects hemolysis in vacuum tubes and blood gas samples. It serves emergency departments in the European Union and the United States.
Bio Vitos Pharma AB (publ) Fundamentals Summary
| BIOVIT fundamental statistics | |
|---|---|
| Market cap | kr67.04m |
| Earnings (TTM) | -kr12.87m |
| Revenue (TTM) | kr3.00m |
22.4x
P/S Ratio-5.2x
P/E RatioIs BIOVIT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIOVIT income statement (TTM) | |
|---|---|
| Revenue | kr3.00m |
| Cost of Revenue | kr1.01m |
| Gross Profit | kr1.98m |
| Other Expenses | kr14.85m |
| Earnings | -kr12.87m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.044 |
| Gross Margin | 66.21% |
| Net Profit Margin | -429.54% |
| Debt/Equity Ratio | 0% |
How did BIOVIT perform over the long term?
See historical performance and comparison